{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "status": "retrieved", "company": "IRLAB Therapeutics", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:25:28Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari - mars 2026", "category": "Interimsrapport", "date": "2026-05-06", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bac2e7970971b6dee153f44604e4bfd08&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "IRLAB Q1 2026 SWE Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/a87c6b7713f581fc9283b5b380be76ca6", "final_url": "https://attachment.news.eu.nasdaq.com/a87c6b7713f581fc9283b5b380be76ca6", "filename": "IRLAB_Q1_2026_SWE_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2026-q1\\IRLAB_Q1_2026_SWE_Final.pdf", "content_type": "application/pdf", "size": 591664, "sha256": "505b54a29eaa6a93bf41402ed03679fe073606a2cd013d7c22f34f3f8c322dd5", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2026-q1\\IRLAB_Q1_2026_SWE_Final.pdf", "filename": "IRLAB_Q1_2026_SWE_Final.pdf", "extension": ".pdf", "size": 591664, "sha256": "505b54a29eaa6a93bf41402ed03679fe073606a2cd013d7c22f34f3f8c322dd5", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2026-q1\\extracted\\IRLAB_Q1_2026_SWE_Final\\IRLAB_Q1_2026_SWE_Final.txt", "text_chars": 64339, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2026-q1\\extracted\\IRLAB_Q1_2026_SWE_Final\\IRLAB_Q1_2026_SWE_Final.extraction.json" } } ], "announcement_id": "1439925", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:25:41Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar årsredovisning för 2025", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-04-29", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=baa536c9dcacc3328fe02db5b0797b2c0&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "IRLAB AR 2025 Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/a08f90ae9f03475896d18a02f6d5b699a", "final_url": "https://attachment.news.eu.nasdaq.com/a08f90ae9f03475896d18a02f6d5b699a", "filename": "IRLAB_AR_2025_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-annual\\IRLAB_AR_2025_Final.pdf", "content_type": "application/pdf", "size": 20163013, "sha256": "b398d00744eb567bb06f1835db007e9b595168a464cf4dce9f6d11f192e85b88", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-annual\\IRLAB_AR_2025_Final.pdf", "filename": "IRLAB_AR_2025_Final.pdf", "extension": ".pdf", "size": 20163013, "sha256": "b398d00744eb567bb06f1835db007e9b595168a464cf4dce9f6d11f192e85b88", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-annual\\extracted\\IRLAB_AR_2025_Final\\IRLAB_AR_2025_Final.txt", "text_chars": 305823, "metadata": { "page_count": 71, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-annual\\extracted\\IRLAB_AR_2025_Final\\IRLAB_AR_2025_Final.extraction.json" } } ], "announcement_id": "1438342", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:25:44Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari - december 2025", "category": "Bokslutskommuniké", "date": "2026-02-25", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3681710b0170c4d7a81e9bf501ddb949&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "IRLAB Bokslutskommunike 2025 Janauri December SWE FINAL.pdf", "url": "https://attachment.news.eu.nasdaq.com/a48787c44f5366998963665e14d608ab4", "final_url": "https://attachment.news.eu.nasdaq.com/a48787c44f5366998963665e14d608ab4", "filename": "IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_FINAL.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q4\\IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_FINAL.pdf", "content_type": "application/pdf", "size": 589385, "sha256": "8917d995eeda295c1c407c7b77047790a2f1ba2ae93c17920902bb736a8bef8d", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q4\\IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_FINAL.pdf", "filename": "IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_FINAL.pdf", "extension": ".pdf", "size": 589385, "sha256": "8917d995eeda295c1c407c7b77047790a2f1ba2ae93c17920902bb736a8bef8d", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q4\\extracted\\IRLAB_Bokslutskommunike_2025_Janauri_December\\IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_.txt", "text_chars": 66724, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q4\\extracted\\IRLAB_Bokslutskommunike_2025_Janauri_December\\IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_.extraction.json" } } ], "announcement_id": "1422336", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:25:49Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari - september 2025", "category": "Interimsrapport", "date": "2025-10-29", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b7929cb4c562f8434dcd68ed2a24aa5eb&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "IRLAB Q3 2025 SVE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a3ba9467d849249338ab8792cb61df4b3", "final_url": "https://attachment.news.eu.nasdaq.com/a3ba9467d849249338ab8792cb61df4b3", "filename": "IRLAB_Q3_2025_SVE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q3\\IRLAB_Q3_2025_SVE.pdf", "content_type": "application/pdf", "size": 591394, "sha256": "928ee49df5c30450024cec6bdc2270377b083d96c0a99d932cacadee38b4e448", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q3\\IRLAB_Q3_2025_SVE.pdf", "filename": "IRLAB_Q3_2025_SVE.pdf", "extension": ".pdf", "size": 591394, "sha256": "928ee49df5c30450024cec6bdc2270377b083d96c0a99d932cacadee38b4e448", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q3\\extracted\\IRLAB_Q3_2025_SVE\\IRLAB_Q3_2025_SVE.txt", "text_chars": 64430, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q3\\extracted\\IRLAB_Q3_2025_SVE\\IRLAB_Q3_2025_SVE.extraction.json" } } ], "announcement_id": "1397240", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:25:54Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari - juni 2025", "category": "Halvårsrapport", "date": "2025-08-27", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3ead9f8ea853de98bb4a89098c78b2e8&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "IRLAB Q2 FINAL SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a31d3ebef0648ca7e0eeb33d8e7266b8b", "final_url": "https://attachment.news.eu.nasdaq.com/a31d3ebef0648ca7e0eeb33d8e7266b8b", "filename": "IRLAB_Q2_FINAL_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q2\\IRLAB_Q2_FINAL_SE.pdf", "content_type": "application/pdf", "size": 386653, "sha256": "03c14f5469d2b82ba9f7cf702eac7ad9c91f0bee2d0a9de930f2dc7d58199329", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q2\\IRLAB_Q2_FINAL_SE.pdf", "filename": "IRLAB_Q2_FINAL_SE.pdf", "extension": ".pdf", "size": 386653, "sha256": "03c14f5469d2b82ba9f7cf702eac7ad9c91f0bee2d0a9de930f2dc7d58199329", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q2\\extracted\\IRLAB_Q2_FINAL_SE\\IRLAB_Q2_FINAL_SE.txt", "text_chars": 60171, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q2\\extracted\\IRLAB_Q2_FINAL_SE\\IRLAB_Q2_FINAL_SE.extraction.json" } } ], "announcement_id": "1385409", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:00Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari - mars 2025", "category": "Interimsrapport", "date": "2025-05-07", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4dbcd7fac0277fe4ff017a6db8554524&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "IRLAB Q1 FINAL SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a1f353db402d76b5479bf0040f1c3cce6", "final_url": "https://attachment.news.eu.nasdaq.com/a1f353db402d76b5479bf0040f1c3cce6", "filename": "IRLAB_Q1_FINAL_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q1\\IRLAB_Q1_FINAL_SE.pdf", "content_type": "application/pdf", "size": 389288, "sha256": "5ac7796a165c826ffb3920a3b34fb66ee08a1033afdbd750f5536ef4e1a5f478", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q1\\IRLAB_Q1_FINAL_SE.pdf", "filename": "IRLAB_Q1_FINAL_SE.pdf", "extension": ".pdf", "size": 389288, "sha256": "5ac7796a165c826ffb3920a3b34fb66ee08a1033afdbd750f5536ef4e1a5f478", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q1\\extracted\\IRLAB_Q1_FINAL_SE\\IRLAB_Q1_FINAL_SE.txt", "text_chars": 59022, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2025-q1\\extracted\\IRLAB_Q1_FINAL_SE\\IRLAB_Q1_FINAL_SE.extraction.json" } } ], "announcement_id": "1361275", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:12Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar årsredovisning för 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-04-25", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b6333f0fe3eb45a89c1a0c519e8add71a&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "IRLAB Arsredovisning 2025 Lowres.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac4a1932700de0a546597011645bdf448", "final_url": "https://attachment.news.eu.nasdaq.com/ac4a1932700de0a546597011645bdf448", "filename": "IRLAB_Arsredovisning_2025_Lowres.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-annual\\IRLAB_Arsredovisning_2025_Lowres.pdf", "content_type": "application/pdf", "size": 10812197, "sha256": "bc8fcbfb01a527e6bdd643048fa5dbe5dd3801df7ba92c594be73d58c1254748", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-annual\\IRLAB_Arsredovisning_2025_Lowres.pdf", "filename": "IRLAB_Arsredovisning_2025_Lowres.pdf", "extension": ".pdf", "size": 10812197, "sha256": "bc8fcbfb01a527e6bdd643048fa5dbe5dd3801df7ba92c594be73d58c1254748", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-annual\\extracted\\IRLAB_Arsredovisning_2025_Lowres\\IRLAB_Arsredovisning_2025_Lowres.txt", "text_chars": 290897, "metadata": { "page_count": 70, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-annual\\extracted\\IRLAB_Arsredovisning_2025_Lowres\\IRLAB_Arsredovisning_2025_Lowres.extraction.json" } } ], "announcement_id": "1358454", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:14Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar bokslutskommuniké för 2024", "category": "Bokslutskommuniké", "date": "2025-02-12", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b62c405c57bf2b81dac0fd7ccc752fdaa&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "IRLAB Q4 SVE 2025 02 12.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac65fdb073394f8e0661529ce41b2a0d3", "final_url": "https://attachment.news.eu.nasdaq.com/ac65fdb073394f8e0661529ce41b2a0d3", "filename": "IRLAB_Q4_SVE_2025_02_12.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q4\\IRLAB_Q4_SVE_2025_02_12.pdf", "content_type": "application/pdf", "size": 380044, "sha256": "cf9867387056374714f0d929e163622e53c4d747347a02e5ba4a70675520bc10", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q4\\IRLAB_Q4_SVE_2025_02_12.pdf", "filename": "IRLAB_Q4_SVE_2025_02_12.pdf", "extension": ".pdf", "size": 380044, "sha256": "cf9867387056374714f0d929e163622e53c4d747347a02e5ba4a70675520bc10", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q4\\extracted\\IRLAB_Q4_SVE_2025_02_12\\IRLAB_Q4_SVE_2025_02_12.txt", "text_chars": 59877, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q4\\extracted\\IRLAB_Q4_SVE_2025_02_12\\IRLAB_Q4_SVE_2025_02_12.extraction.json" } } ], "announcement_id": "1342291", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:19Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari - september 2024", "category": "Interimsrapport", "date": "2024-10-30", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b75f15362c96e9c2427dcba54fa88f2c9&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "IRLAB Q3 2024 SVE.pdf", "url": "https://attachment.news.eu.nasdaq.com/aa88601b14548120afa4692d054312648", "final_url": "https://attachment.news.eu.nasdaq.com/aa88601b14548120afa4692d054312648", "filename": "IRLAB_Q3_2024_SVE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q3\\IRLAB_Q3_2024_SVE.pdf", "content_type": "application/pdf", "size": 382898, "sha256": "c7a90c457983af2c8fc9db92d1c51ddf7ebc39a3d34568046704eecbcfaec9f8", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q3\\IRLAB_Q3_2024_SVE.pdf", "filename": "IRLAB_Q3_2024_SVE.pdf", "extension": ".pdf", "size": 382898, "sha256": "c7a90c457983af2c8fc9db92d1c51ddf7ebc39a3d34568046704eecbcfaec9f8", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q3\\extracted\\IRLAB_Q3_2024_SVE\\IRLAB_Q3_2024_SVE.txt", "text_chars": 61821, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q3\\extracted\\IRLAB_Q3_2024_SVE\\IRLAB_Q3_2024_SVE.extraction.json" } } ], "announcement_id": "1324436", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:25Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari-juni 2024", "category": "Halvårsrapport", "date": "2024-07-10", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b1a932c7e411d1522abffc928eb926ea1&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "IRLAB Q2 2024 SVE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a8fe2f4726a5dbc7f4f772724efc021d6", "final_url": "https://attachment.news.eu.nasdaq.com/a8fe2f4726a5dbc7f4f772724efc021d6", "filename": "IRLAB_Q2_2024_SVE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q2\\IRLAB_Q2_2024_SVE.pdf", "content_type": "application/pdf", "size": 347762, "sha256": "7261d5991584403d422756691cb5fae45edb9e4dc2010a530f649262f8534780", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q2\\IRLAB_Q2_2024_SVE.pdf", "filename": "IRLAB_Q2_2024_SVE.pdf", "extension": ".pdf", "size": 347762, "sha256": "7261d5991584403d422756691cb5fae45edb9e4dc2010a530f649262f8534780", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q2\\extracted\\IRLAB_Q2_2024_SVE\\IRLAB_Q2_2024_SVE.txt", "text_chars": 54432, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q2\\extracted\\IRLAB_Q2_2024_SVE\\IRLAB_Q2_2024_SVE.extraction.json" } } ], "announcement_id": "1305778", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:30Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari-mars 2024", "category": "Interimsrapport", "date": "2024-05-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b382108fa4f0ea3918dfb1ad2b2086216&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "IRLAB Q1 24 Final SVE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a283d252335a38071c82196bacb1f08ba", "final_url": "https://attachment.news.eu.nasdaq.com/a283d252335a38071c82196bacb1f08ba", "filename": "IRLAB_Q1_24_Final_SVE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q1\\IRLAB_Q1_24_Final_SVE.pdf", "content_type": "application/pdf", "size": 327957, "sha256": "fe521fb4271cf01c8b83263caf2e6ff835645a69ac731cbe1acad4a4d65ab8a0", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q1\\IRLAB_Q1_24_Final_SVE.pdf", "filename": "IRLAB_Q1_24_Final_SVE.pdf", "extension": ".pdf", "size": 327957, "sha256": "fe521fb4271cf01c8b83263caf2e6ff835645a69ac731cbe1acad4a4d65ab8a0", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q1\\extracted\\IRLAB_Q1_24_Final_SVE\\IRLAB_Q1_24_Final_SVE.txt", "text_chars": 53733, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2024-q1\\extracted\\IRLAB_Q1_24_Final_SVE\\IRLAB_Q1_24_Final_SVE.extraction.json" } } ], "announcement_id": "1294242", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:44Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar årsredovisning för 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-04-29", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b2faf8be30c856129c7430454064a4244&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "IRLAB Arsredovisning 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a680177f5f7902bb9c2b64c8ac8783bcc", "final_url": "https://attachment.news.eu.nasdaq.com/a680177f5f7902bb9c2b64c8ac8783bcc", "filename": "IRLAB_Arsredovisning_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-annual\\IRLAB_Arsredovisning_2023.pdf", "content_type": "application/pdf", "size": 7786610, "sha256": "8376ba43757e9f2515a2cb30dca7357684e494cf3ba8e5bc3bceb1784e900be5", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-annual\\IRLAB_Arsredovisning_2023.pdf", "filename": "IRLAB_Arsredovisning_2023.pdf", "extension": ".pdf", "size": 7786610, "sha256": "8376ba43757e9f2515a2cb30dca7357684e494cf3ba8e5bc3bceb1784e900be5", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-annual\\extracted\\IRLAB_Arsredovisning_2023\\IRLAB_Arsredovisning_2023.txt", "text_chars": 288962, "metadata": { "page_count": 70, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-annual\\extracted\\IRLAB_Arsredovisning_2023\\IRLAB_Arsredovisning_2023.extraction.json" } } ], "announcement_id": "1291865", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:46Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar bokslutskommuniké för perioden januari-december 2023", "category": "Bokslutskommuniké", "date": "2024-02-07", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b8b3bfc3c4952ac57e1edd96aff953504&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "IRLAB Bokslutskommunike 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/adda82490b9cd45873daa2c13d1a42a2f", "final_url": "https://attachment.news.eu.nasdaq.com/adda82490b9cd45873daa2c13d1a42a2f", "filename": "IRLAB_Bokslutskommunike_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q4\\IRLAB_Bokslutskommunike_2023.pdf", "content_type": "application/pdf", "size": 320761, "sha256": "909162dbd9614fee71d5e70483759de69c87753a4fb3c235a0008e0f84bb31eb", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q4\\IRLAB_Bokslutskommunike_2023.pdf", "filename": "IRLAB_Bokslutskommunike_2023.pdf", "extension": ".pdf", "size": 320761, "sha256": "909162dbd9614fee71d5e70483759de69c87753a4fb3c235a0008e0f84bb31eb", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q4\\extracted\\IRLAB_Bokslutskommunike_2023\\IRLAB_Bokslutskommunike_2023.txt", "text_chars": 56219, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q4\\extracted\\IRLAB_Bokslutskommunike_2023\\IRLAB_Bokslutskommunike_2023.extraction.json" } } ], "announcement_id": "1273092", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:52Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari-september 2023", "category": "Interimsrapport", "date": "2023-10-25", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b437a375968b71a74800487bc89143c8d&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "IRLAB Delarsrapport Q3 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a9a35737af26033f7b36b6809e73cb2f5", "final_url": "https://attachment.news.eu.nasdaq.com/a9a35737af26033f7b36b6809e73cb2f5", "filename": "IRLAB_Delarsrapport_Q3_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q3\\IRLAB_Delarsrapport_Q3_2023.pdf", "content_type": "application/pdf", "size": 698270, "sha256": "618eb6cb64f39e88e7d435f572de1f79e8103b1f7ee2a9f3dd48042ccdef06e3", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q3\\IRLAB_Delarsrapport_Q3_2023.pdf", "filename": "IRLAB_Delarsrapport_Q3_2023.pdf", "extension": ".pdf", "size": 698270, "sha256": "618eb6cb64f39e88e7d435f572de1f79e8103b1f7ee2a9f3dd48042ccdef06e3", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q3\\extracted\\IRLAB_Delarsrapport_Q3_2023\\IRLAB_Delarsrapport_Q3_2023.txt", "text_chars": 54885, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q3\\extracted\\IRLAB_Delarsrapport_Q3_2023\\IRLAB_Delarsrapport_Q3_2023.extraction.json" } } ], "announcement_id": "1254506", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:26:56Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari-juni 2023", "category": "Halvårsrapport", "date": "2023-08-30", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4a1cd1568099a10abdbf6b456e09cec4&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "IRLAB Delarsrapport Q2 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a06944ca44a858fbd57afb56e67641dcc", "final_url": "https://attachment.news.eu.nasdaq.com/a06944ca44a858fbd57afb56e67641dcc", "filename": "IRLAB_Delarsrapport_Q2_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q2\\IRLAB_Delarsrapport_Q2_2023.pdf", "content_type": "application/pdf", "size": 876968, "sha256": "d658b6246c4a52f07c9bdd58ef5155ff9c73f18772353d15b5511f82599d5395", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q2\\IRLAB_Delarsrapport_Q2_2023.pdf", "filename": "IRLAB_Delarsrapport_Q2_2023.pdf", "extension": ".pdf", "size": 876968, "sha256": "d658b6246c4a52f07c9bdd58ef5155ff9c73f18772353d15b5511f82599d5395", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q2\\extracted\\IRLAB_Delarsrapport_Q2_2023\\IRLAB_Delarsrapport_Q2_2023.txt", "text_chars": 56836, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q2\\extracted\\IRLAB_Delarsrapport_Q2_2023\\IRLAB_Delarsrapport_Q2_2023.extraction.json" } } ], "announcement_id": "1245184", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T04:27:01Z", "company": "IRLAB Therapeutics AB", "title": "IRLAB publicerar delårsrapport för perioden januari-mars 2023", "category": "Interimsrapport", "date": "2023-05-10", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b47ae27d3a5657ed942eee368ce3a4c0f&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "IRLAB Delarsrapport Q1 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a35f1abb0bd3293f977d871a5c05f21b9", "final_url": "https://attachment.news.eu.nasdaq.com/a35f1abb0bd3293f977d871a5c05f21b9", "filename": "IRLAB_Delarsrapport_Q1_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q1\\IRLAB_Delarsrapport_Q1_2023.pdf", "content_type": "application/pdf", "size": 1032308, "sha256": "1dc1c34123f46504928637e587beda0a970ed7ff02c96aed652de0bbde749a2a", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q1\\IRLAB_Delarsrapport_Q1_2023.pdf", "filename": "IRLAB_Delarsrapport_Q1_2023.pdf", "extension": ".pdf", "size": 1032308, "sha256": "1dc1c34123f46504928637e587beda0a970ed7ff02c96aed652de0bbde749a2a", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q1\\extracted\\IRLAB_Delarsrapport_Q1_2023\\IRLAB_Delarsrapport_Q1_2023.txt", "text_chars": 65900, "metadata": { "page_count": 27, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\irlab-therapeutics\\nasdaq-reports\\reports\\2023-q1\\extracted\\IRLAB_Delarsrapport_Q1_2023\\IRLAB_Delarsrapport_Q1_2023.extraction.json" } } ], "announcement_id": "1226724", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "2fdb468939444aaea180c1459c6d3c21ed12068f96e65e1bbc7e100512db6b35" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "e3bd6bf253e3e3c7ad2b4ca10161cb16835d9dc9fc8833d028ae0060c9df39a6" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 200, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 55, "new_rows": 55, "total_count": null, "from_cache": false, "body_sha256": "0404c8307d689e190840e1bcd796de27c2e719944fe7dcf32c6b08dad669219a" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=255&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 255, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "e5d11078c7aebeba7d6b88fcd85d8f612d635bb4193e1f67e99b0d17c6489b87" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 3, "new_rows": 3, "total_count": null, "from_cache": false, "body_sha256": "1e120d7458ba893808c81d6dadf2d57006d143e94ac1683c11a0fb534a370e44" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=3&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 3, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "449de37c3458e07fa7a04e480e0ef1298d825283b8c7f36964108a8672015b9a" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "09347dddb02b6a3482f12d7732b1adb5fcf54ff864b7166b8ab11b1fa429604b" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "3533fa3976e332d98933269963296e4b6971a0e44018ab9f6e2be8d2fe54b844" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 200, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 23, "new_rows": 23, "total_count": null, "from_cache": false, "body_sha256": "a76d0b4398d8b7c1635b2366a9a3fb6a11fcbf7ac8db81397a680009aeed19d5" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=223&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 223, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "4cd0306eb78d01175fa9e0a353cd364969251413f3e7c405c969fa2eaf453431" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 2, "new_rows": 2, "total_count": null, "from_cache": false, "body_sha256": "c32bcbc2733d636a4b273c3ef2fe7af225789b02f47c1374f463eaea192994c0" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=IRLAB+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=2&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 2, "pagination": "row-offset", "query_text": "IRLAB Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "8cf81a327a3a8b325adfd784ef5b23173c052fd172113cb13a000ad4e443c411" } ], "identity": { "slug": "", "instrument_id": "TX2308898", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/irlab-a?id=TX2308898" }, "transport": "ordinary-http", "browser_used": false, "query_text": "IRLAB Therapeutics", "retrieved_at": "2026-08-07T04:27:02Z" }